We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Businesses recruit when they have a demand due to existing or forthcoming contracts.
You can pursue new business streams all you want, doesn't mean you'll get them.
In the past there was not a lot of recruitment, but in the last couple of years this has changed, as has the company, in that we are pursuing new business streams. I'm not saying we are recession proof but cancer and personalised medicine research does seem to be in a critical stage with many companies involved.
The recent recruitments, including a NED, show the confidence of the BoD. Personally I think this confidence is justified and I'm looking forward to a full year trading update in a couple of months or so. Onwards and upwards!
The company clearly stated that since mid 2021 they have decided to spend money on recruitment and development, hence why in the financial year June 2021 onwards there was more spending from the company due to growth and expansion
>Our cash position is pretty stable. In the full year ended 30 June 2021 our net change in cash was a reduction of just ~£5k. In each of the last two full financial years we’ve maintained cash and equivalents of over £1m. Now we may choose selectively to make some investments from that cash pile (as we have done in hiring a new BD lead for example), but we want to be cautious and leave ourselves a reserve float just in case of unexpected circumstances
See the annual accounts
The extra spend was on recruitment of 3+ new personal which they chose and planned to spend
The Costs of the operating business (net cash used I operating activities) is c £40k
riddler's always good at gloss
From the last annual accounts & interims:
Cash and cash equivalents at 30 June 2021 of £1,043,450
Cash and cash equivalents of £794k at 31 December 2021
So, in 6 months cash decreased by around £250k. How do you get cash burn of '£30k or so per annum'?
Is is very very poor volume across the whole market....the £3.8mln cap does not reflect the progress here
We have a very very low cash burn (£30k or so per annum) amd therefore PYC are in far better position than most small caps as PYC has 1/4 of the value as cash and we knowbthat the VAL201 deal is coming as shown in the VAL annual report
There are 100s of stocks also suffering from low liquidity
Sienna
What did you ask/email to PYC ?
Most AIM shares are down over the last few months or so, and in particular those who are not in profit. Not to certain though who is in control of any individual SP? It's usually considered 'market forces' - whatever that is!
This is bad for shareholders. I've complained here before but no one in control seems concerned about this!!!
With the constant drip drip drip of 30k sells, which has been going on for weeks now, and hardly any buys recently, the SP is very close to the fund raise of May 27th 2020 of 3.5p.
Further analysis has been completed from a commercial viewpoint of considering the data with independent Key Opinion Leaders and an expert team on valuation benchmarking. Further scientific analysis has been carried out in collaboration with Physiomics, as announced on 15 February 2021, who have been considering the clinical data in conjunction with the historic preclinical data and the newly generated pre-clinical data generated across the VAL301 and BC201 projects.
Look at VAL RNS last night and how much cash they have and the loss last year yet the SP is up!
MCAP here is too low IMHO
Since last week 30k sell off everyday, before that we had 50k sells just about every day.
Looks like everything on AIM is struggling for volume since the sad events in Ukraine
But cream will rise to the top
I only have 3 small cap shares and PYC is one of them
I've gone for large cap dividend players too
Maybe THX will use us for more assets in the pre clinical pipeline?
Maybe VAL announce the 201 deal soon?
Maybe PYC announce the news on several fronts we all await for?
Lots of maybe's, but what is 100% certain is that the SP is eroding quicker than the Norfolk coastline. 30k sells day in, day out with little buying appearing.
#endofrant.
It is for period ended December 2021 but has this mention regarding VAL201
. We also see TheoremRx as a prospective partner for assets in our pre-clinical pipeline. We continue to support TheoremRx in their scientific activities and look forward to a successful fund raise in the near future.
Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care in core tumors and assess the potential of novel mechanisms of action, including an industry-leading portfolio of DNA Damage Response inhibitors (DDRi), the company continues to build its focused leadership in the oncology space.
“Within our clinical-stage pipeline and our discovery programs, we have the opportunity to unlock and address DNA biology and apply a diversity of mechanisms to the treatment of multiple cancers
BACK
ABOUT US
COMPANYStrategy & ValuesManagementMerck HistoryBreakthroughs begin with CuriosityMerck in GermanyMerck LocationsContact UsSUSTAINABILITYProducts & InnovationBusiness EthicsHealth for AllEnvironmentEmployeesCommunity EngagementReports & GuidelinesSustainability ReportPARTNERINGCollaboration in HealthcareCollaboration in Life ScienceCollaboration in ElectronicsAcceleratorM VenturesProcurement
BACK
EXPERTISE
HEALTHCAREOncologyNeurology & ImmunologyFertilityEndocrinologyGeneral MedicineVibrant Thoughts BlogLIFE SCIENCEPharma BiotechDiagnosticsAcademic and Government ResearchIndustrialELECTRONICSSemiconductor SolutionsDisplay SolutionsSurface SolutionsArchitectureAutomotive
BACK
SCIENCE & TECH
RESEARCHOur R&D ApproachHealthcare PipelineClinical TrialsGlobal R&D HubsArtificial Intelligence - AI ResearchINNOVATION CENTERInnovation FieldsProject HighlightsGet involved!NewsEventsOPEN INNOVATIONFuture Insight Prize2022 Research Grants2022 Research ChallengesInnovation CupGrants and AwardsAll Open Innovation OffersSCIENCE SPACEEnvisioning TomorrowExperience our ResearchScience Library - Patents & Publications
Ralph. Interesting. So are you saying the 2 are linked? If so could we have possibly an rns this week Bout it?
Thanks Ralph
Is the Merck update linked to the previous PYC RNS before Christmas?
I just posted this on Pyc Telegram bb.
13 Dec contract with Merck
“These projects are expected to be completed over the course of the next six months and will span a range of drug targets and treatment types in both pre-clinical and clinical settings with a particular focus on DNA damage and repair (“DDR”) agents.”
3rd June Merck announces,
New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology
Clinical trials in locally advanced head and neck cancer and advanced bladder cancer seek to advance standards of care
https://www.merckgroup.com/en/news/development-projects-in-oncology-03-06-2022.html
https://www.bbc.co.uk/iplayer/episode/m0017wzq/horizon-2022-making-sense-of-cancer-with-hannah-fry
interesting as the conclusion is that "one size fits all" mantra of Cancer treatment, should be superseded by a different approach, a approach that PYC have advocated for sometime.
Also, S4, that was your funniest (in a good way ) post yet.
shame you guys can't "report" the share price.
Hi Siennaj, I've got one from you on Tuesday at 00:13 an d one from Laura at 07:43 also on Tuesday. The next one I've got yours at 13:53 on Thursday. More than one poster removed I think. I didn't read any thing contentious in any of the posts. All a bit strange!